650 E Kendall Street
About BaxaltaBaxalta Incorporated (NYSE: BXLT) is a $6 billion global biopharmaceutical leader developing, manufacturing and commercializing therapies for orphan diseases and underserved conditions in hematology, oncology and immunology. Driven by passion to make a meaningful impact on patients’ lives, Baxalta’s broad and diverse pipeline includes biologics with novel mechanisms and advanced technology platforms such as gene therapy. The Baxalta Global Innovation and R&D Center is located in Cambridge, Massachusetts. Launched in 2015 following separation from Baxter International, Baxalta’s heritage in biopharmaceuticals spans decades. Baxalta’s therapies are available in more than 100 countries and it has advanced biological manufacturing operations across 12 facilities, including state-of-the-art recombinant production and plasma fractionation. Headquartered in Northern Illinois, Baxalta employs 16,000 employees worldwide.
CEO: Ludwig Hantson
CFO: Robert Hombach
CSO (Scientific): John Orloff
Please click here for Baxalta job opportunitites.
Please click here for clinical trial information.
PRODUCTS: All Products
FOLLOW BAXALTA : Tweets by Baxalta
125 articles with Baxalta
Halozyme Therapeutics announced that it is acquiring Antares Pharma for $960 million in cash. The news caused Antares stock to rocket 47% in premarket trading.
Silence Therapeutics, Totus Medicines and Poseida Therapeutics all adjust as they welcome new members to their leadership teams.
Takeda Pharmaceutical released data from its Phase IIIb/IV clinical trial for Adynovate. On the same day, jurors in a Delaware federal court ordered Takeda’s Baxalta unit to pay $155.19 million to Bayer AG for infringing a patent for Adynovate.
Virion Therapeutics, LLC Announces its Inaugural Board of Directors and Scientific Advisory Board Members
Virion Therapeutics, LLC today announced the appointment of its inaugural Board of Directors and Scientific Advisory Board.
Steven Hamburger, Ph.D. appointed as Vice President, Regulatory Affairs and Laura Mei appointed as Vice President, Clinical Operations.
Shire Announces Early Results Of The Previously Announced Cash Tender Offers For Certain Outstanding Notes
As of 5:00 p.m. New York City time, on September 7, 2018 (the "Early Tender Date"), the principal amounts of the Notes listed in the table below had been validly tendered and not validly withdrawn.
Halozyme Therapeutics, Inc. will present data evaluating certain biomarkers as potential predictors of survival in patients with previously untreated metastatic pancreatic ductal adenocarcinoma at the American Society of Clinical Oncology annual meeting.
Precision medicine company names Chief Medical Officer, Chief Business Officer and Chief Technology Officer.
The ink is still drying on the contracts for Japan’s Takeda Pharmaceutical’s acquisition of Dublin-based Shire for about $62.2 billion, but company executives are sharing some of the “inside baseball” about what went on behind the scenes of the deal.
Yesterday’s news that Takeda Pharmaceuticals was considering acquiring Shire is raising the possibility of a bidding war. But it’s also having decidedly different effects on the two companies’ stock prices.
Shire stock prices jumped up to 26 percent on rumors that Takeda Pharmaceuticals was considering a buyout.
Xenetic Biosciences Enters Into Sublicense Agreement Related to its PolyXen Technology With Baxalta, a Wholly-owned Subsidiary of Shire plc
As part of the Sublicense Agreement, Baxalta agreed to pay Xenetic a one-time payment of $7.5 million and single digit royalty payments based upon net sales of the products covered under the sublicense throughout the term of the agreement.
In 3Q Report, Shire Breaks Out Data From Baxalta Acquisition and Announces Several Program Terminations
Editas Medicine Brings on New Execs From Sanofi Genzyme, Novartis AG, Baxalta and Bristol-Myers Squibb